Fig. 3: Clinical validation of the mt-IDH1dx assay and statistical evaluation of its diagnostic performance using plasma derived Extracellular Vesicle RNA.
From: Clinical utility of a blood based assay for the detection of IDH1.R132H-mutant gliomas
a Schematic summarizing the study population (N = 133) for blinded validation testing in three independent cohorts. Sensitivity and Specificity calculated for the individual cohorts and the combined study population. Area under curve (AUC) analysis performed to measure assay efficiency. This was done using Wilson/Brown method with results demonstrating an Area 0.8392 and standard error 0.03775 (95% CI: 0.7652–0.9131, p value < 0.0001). b A comparison of assay the sensitivity, specificity, and accuracy in the study population stratified by histological diagnosis (Astrocytoma, Grade 2–3, Oligodendroglioma, Grade 2–3, and Astrocytoma, Grade 4). Source Data are provided in Supplementary Tables 2, 3.
